25 July 2018 - - San Diego, California-based central nervous system disorders therapeutics developer Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has appointed Austin D. Kim as executive vice president, general counsel and secretary, the company said.
He will report to Steve Davis, Acadia's president and chief executive officer and serve as a member of the company's executive management committee.
The company previously announced in February that Glenn F. Baity, who served as executive vice president, general counsel and secretary since 2004, would be retiring. Baity will remain with Acadia through completion of a transition period.
From 2006 until 2017, Kim held several senior legal positions at Teva Pharmaceuticals. Before joining Teva, he was deputy general counsel at IVAX Corp.
Earlier in his career, Kim was a senior lawyer at Transamerica Corp., practiced law at Pillsbury, Madison and Sutro and clerked for Judge Vaughn Walker of the US District Court, Northern District of California.
Kim received his J.D. degree from Columbia University School of Law and his A.B. in English Literature and Economics from Stanford University.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.